Supports Research Activities for AnaptysBio’s Internal and Partnered Programs
Guildford, UK, and Burlington, Mass., February 22, 2011 – IDBS, a global provider of innovative enterprise data management, analytics and modeling solutions, today announced that AnaptysBio, Inc., an emerging U.S. biotechnology company, has adopted IDBS’ E-WorkBook Suite to manage research data generated using its SHM-XEL™ antibody discovery and optimization platform. Therapeutic antibodies are widely regarded as the fastest growing segment of the pharmaceutical industry.
AnaptysBio is the leader in the in vitro application of somatic hypermutation (SHM) for antibody discovery and optimization. SHM is the body’s natural process for generating potent antibodies to fight disease. AnaptysBio’s SHM-XEL™ platform couples SHM with mammalian cell expression, secretion and display, deep sequencing, and flow cytometry to generate antibodies for therapeutic applications through a process of natural evolution and high-throughput selection. This versatile platform is being used for both discovery of new antibodies and optimization of existing antibodies to generate product candidates for its internal pipeline and partners.
E-WorkBook provides AnaptysBio with searchable, scalable and secure information management that is applicable across their business, improving internal and external collaboration, process efficiency and data consistency. E-WorkBook enables AnaptysBio to secure unparalleled context with their data, to search, annotate and report swiftly on their results and to meet their scientific goals.
“Research productivity is a priority for industry, including the ability to timely and comprehensively collect, retrieve and analyze data,” said Tom Smart, Chairman and CEO of AnaptysBio. “We look forward to utilizing E-WorkBook to provide us with greater visibility and control of data generated using our SHM-XELTM platform, and enhance our ability to search, retrieve and generate reports for scientific analysis.”
“E-WorkBook applications enable customers to extract maximum information value from their enterprise data and is a foundation for pioneering therapeutic research such as SHM,” said Neil Kipling, founder and CEO of IDBS. “AnaptysBio’s technology represents a unique and innovative approach that offers the promise of expanding treatment options for a wide range of diseases, and we are delighted to be supporting their research.”
Founded in 2005, AnaptysBio, Inc. is a privately-held therapeutic antibody product company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body’s natural process for generating potent antibodies to fight disease. The Company’s SHM-XEL™ platform couples SHM with mammalian cell expression, secretion and display, deep sequencing, and flow cytometry to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection – a process that has been referred to as ‘naturalizing’ antibodies. This versatile platform can be used for both discovery of new antibodies and optimization of existing antibodies to generate candidates with desired binding and specificity properties for therapeutic applications. AnaptysBio has established broad intellectual property around the use of SHM, and is currently building a pipeline of novel therapeutic antibody product candidates. Major investors in AnaptysBio include founding investor Avalon Ventures, as well as Alloy Ventures, Frazier Healthcare Ventures, and Novo A/S. In November 2007, AnaptysBio raised $33.9 million in a Series B equity financing led by Novo A/S. For more information, visit www.anaptysbio.com.
IDBS is a global provider of innovative enterprise data management, analytics and modeling solutions. The company’s uniquely sophisticated platform technologies are used by more than 200 pharmaceutical companies, major healthcare providers, global leaders in academic study, and high tech companies to increase efficiency, reduce costs and improve the productivity of industrial R&D and clinical research. IDBS is clearly differentiated by its unique combination of award-winning enterprise technologies and domain knowledge in R&D.
IDBS’ solutions help scientists, hospitals and R&D businesses produce the world’s newest therapeutics, diagnostics and personalized treatments, faster, cleaner engines and fuels, breakthroughs in productive agriculture, healthy, safer food products, and high tech materials and consumer products.
Founded in 1989 and privately held, IDBS is headquartered in Guildford, UK with a direct sales and support presence worldwide. IDBS is a Profit Track 100 company and the recipient of multiple awards including the Frost and Sullivan ‘Enabling Technology’ Award in R&D data management for 2010 and Queen’s Award for International Trade 2011. Further information can be found at www.idbs.com, or follow us on Twitter @IDBSsoftware.